Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372948 | 0.92 | NR2E1 (0.58) | NR2E1 | |
| SCHEMBL10104281 | 0.86 | NR2E1 (0.73) | NR2E1 | |
| SCHEMBL15315567 | 0.84 | NR2E1 (0.54) | NR2E1 | |
| SCHEMBL589390 | 0.83 | NR2E1 (1.00) | NR2E1 | |
| SCHEMBL21950471 | 0.83 | NR2E1 (0.69) | NR2E1 | |
| SCHEMBL12354435 | 0.83 | NR2E1 (0.69) | NR2E1 | |
| SCHEMBL1505804 | 0.83 | NR2E1 (0.69) | NR2E1 | |
| SCHEMBL4454872 | 0.83 | NR2E1 (0.69) | NR2E1 | |
| SCHEMBL1912775 | 0.83 | NR2E1 (0.69) | NR2E1 | |
| Hydrochloric Acid SCHEMBL21462041 | 0.82 | NR2E1 (0.97) | NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325156-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | RUI JIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2020-10-15 | — | — | US | disclosed |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10196378-B2 | Inhibitors of BCR-ABL mutants and use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-05 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180057479-A1 | Inhibitors of BCR-ABL Mutants and Use Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-01 | — | — | US | disclosed |
| US-20180057479-A1 | Inhibitors of BCR-ABL Mutants and Use Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-01 | — | — | US | disclosed |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | NR2E1 1868/4885 |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | NR2E1 1890/4885 |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, MCL1 | NR2E1 1283/4885 |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | NR2E1 2458/4885 |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | CYP3A43, CYP2F1, CYP11B2 | NR2E1 1748/4885 |
| US-20180057479-A1 | Inhibitors of BCR-ABL Mutants and Use Thereof | ABL1, BCR, ABL2 | NR2E1 3161/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | NR2E1 1215/4885 |
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | NR2E1 1890/4885 |
| US-20200325156-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | WEE1, ABCG2, WEE2 | NR2E1 3967/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | NR2E1 1806/4885 |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | NR2E1 1046/4885 |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | DCK, TK1, DTYMK | NR2E1 3413/4885 |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | CYP3A43, CYP2F1, CYP11B2 | NR2E1 1748/4885 |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | NR2E1 3413/4885 |
| US-10196378-B2 | Inhibitors of BCR-ABL mutants and use thereof | ABL1, BCR, ABL2 | NR2E1 3161/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NR2E1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.